key: cord-0965749-pa11qsac
authors: Purroy, Francisco; Arqué, Gloria
title: Influence of thromboembolic events in the prognosis of COVID-19 hospitalized patients. Results from a cross sectional study
date: 2021-06-09
journal: PLoS One
DOI: 10.1371/journal.pone.0252351
sha: f48d20798ad52f57d99e204732511e1ad39e39d8
doc_id: 965749
cord_uid: pa11qsac

BACKGROUND: COVID-19 may predispose to both venous and arterial thromboembolism event (TEE). Reports on the prevalence and prognosis of thrombotic complications are still emerging. OBJECTIVE: To describe the rate of TEE complications and its influence in the prognosis of hospitalized patients with COVID-19 after a cross-sectional study. METHODS: We evaluated the prevalence of TEE and its relationship with in-hospital death among hospitalized patients with COVID-19 who were admitted between 1st March to 20th April 2020 in a multicentric network of sixteen Hospitals in Spain. TEE was defined by the occurrence of venous thromboembolism (VTE), acute ischemic stroke (AIS), systemic arterial embolism or myocardial infarction (MI). RESULTS: We studied 1737 patients with proven COVID-19 infection of whom 276 died (15.9%). TEE were presented in 64 (3.7%) patients: 49 (76.6%) patients had a VTE, 8 (12.5%) patients had MI, 6 (9.4%%) patients had AIS, and one (1.5%) patient a thrombosis of portal vein. TEE patients exhibited a diffuse profile: older, high levels of D-dimer protein and a tendency of lower levels of prothrombin. The multivariate regression models, confirmed the association between in-hospital death and age (odds ratio [OR] 1.12 [95% CI 1.10–1.14], p<0.001), diabetes (OR 1.49 [95% CI 1.04–2.13], p = 0.029), chronic obstructive pulmonary disease (OR 1.61 [95% CI 1.03–2.53], p = 0.039), ICU care (OR 9.39 [95% CI 5.69–15.51], p<0.001), and TTE (OR 2.24 [95% CI 1.17–4.29], p = 0.015). CONCLUSIONS: Special attention is needed among hospitalized COVID-19 patients with TTE and other comorbidities as they have an increased risk of in-hospital death.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) that is now considered a pandemic by the World Health Organization [1] [2] [3] . Although, initial efforts have been focused on the diagnosis and treatment of severe pneumonia with vital compromise [1, 3] , a spectrum of extra respiratory symptoms and signs generated by the infection itself have been verified. Among those symptoms, we can stand out that COVID-19 infection might predispose patients to thrombotic disease, both in the venous and arterial circulations mediated by inflammation, endothelial dysfunction, thrombin generation, platelet activation and stasis [4, 5] . Recently, it was reported a 31% prevalence of thrombotic complications in ICU patients with COVID-19 infections in Dutch intensive care units [6] . Coagulopathy and over disseminated intravascular coagulation appear to be associated with high mortality rates. Among the coagulation parameters, D-dimer elevation was the strongest independent predictor of mortality [7] , and high levels of D-dimer have been observed in patients admitted to intensive care units [1] . Nonsurvivors have shown significantly higher levels of plasma D-dimers and fibrin degradation products, increased prothrombin times and activated partial thromboplastin times compared to survivors [8] . Moreover, the metallopeptidase enzyme of angiotensinogen converter 2 (ACE2), identified as the cellular receptor for the coronavirus, is expressed in alveolar epithelial cells and in endothelial cells [9] . The prothrombotic predisposition seems to be developed more intensely from the tenth day of infection [10] , and it would also be related to the inflammatory effect of the COVID-19 infection.

The relationship between inflammation and ischemic episodes is already described [11, 12] and COVID-19 associated ischemic strokes are more severe with worse functional outcome and higher mortality than non-COVID-19 ischemic strokes patients [13, 14] . COVID-19 has a number of important cardiovascular implications [15] [16] [17] . There is a high prevalence of cardiovascular disease among patients with COVID-19 and acute cardiac injury is commonly observed in severe cases. Patients with prior risk factors are at higher risk for adverse events from COVID-19 and worse prognosis [18, 19] .

Here, we evaluated the prevalence of thromboembolism event (TEE) in all COVID-19 patients admitted to the network of 16 Hospitals in Spain (HM Hospitals). The influence of the composite outcome in the risk of death during the admission was also determined. 2020. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were applied [20] .

A dedicated electronic medical record data extraction protocol was developed to identify all patients with confirmed COVID-19 (defined as a positive SARS-CoV2 reverse-transcriptase polymerase chain reaction test by nasopharyngeal/oropharyngeal swab or sputum specimen). Patients whose age was under 18 years were excluded (n = 11) (Fig 1) . We retrieved the primary International Classification of Diseases (ICD10, 10th Revision, Clinical Modification) codes for each patient. For the selected patients, clinical characteristics, demographic variables, admission at ICU, laboratory determinations, coexisting conditions and vascular risk factors based on ICD10 were collected for further analysis. Patients without ICD10 codification were also excluded (n = 131) (Fig 1) .

The primary outcome was the occurrence of TEE defined by venous thromboembolism (VTE), acute ischemic stroke (AIS), systemic arterial embolism or myocardial infarction. The relationship of TEE with the endpoint of in-hospital discharged or exitus was also evaluated. 

Categorical variables were presented as numbers and percentages and continuous variables as mean and standard deviation if they were normally distributed or median and interquartile range if they were not normally distributed. Variables related to the composite outcome and death were identified. We compared means for continuous variables by using independent group t-tests when the data was normally distributed; otherwise, we used the Mann-Whitney test. Proportions for categorical variables were compared using the chi-square (χ2) test. Fisher's exact test was used in the analysis of contingency when the sample sizes were small. Multivariate logistic regression analysis was used to identify predictors of death, in which variables showing p�0.10 on a univariate testing were included. Forward selection model with likelihood ratio (LR) was used, first demographic and clinical characteristics (model 1) were added and vital signs (model 2) were added afterwards, to analyze the single best improvement of the model. All the tests were 2-sided and were run at a statistical significance level of p�0.05. Data was analyzed using SPSS Statistics software, version 20 (IBM SPSS, Chicago, IL, USA).

The study was approved by the Ethics committee of the HM Hospitals (approval number 20.03.1573-GHM).and adhered to the policy for protection of human subjects according to Declaration of Helsinki. As the information was obtained from a de-identified public database written informed consent for our specific study from all study participants was not needed. The data were analyzed anonymously.

A total of 1737 patients (Fig 1) were included in the current analysis, all of them were COVID-19 positive. Of those, 64 (3.7%) patients had a TEE: 49 (76.6%) patients had a VTE, 8 (12.5%) patients had an acute ischemic heart disease event, 6 (9.4%%) patients had an AIS, and one (1.5%) patient a thrombosis of portal vein. Median time from admission to discharge was 7 (interquartile range [IQR], 4.0-10.0) days. The main diagnosis at admission was pneumonia or respiratory symptoms present in 1606 (92.5%) patients. Hypertension was the main vascular risk factor presented in 647 (37.2%) patients. 117 (6.7%) patients required intensive care. 276 patients died after hospital's admission, corresponding to an in-hospital mortality rate of 15.9%. Median time until death was 5.0 days (IQR 3.0-9.0) days.

Dataset was clustered by the absence/presence of TEE ( (Table 3 ).

Our results showed a deleterious effect of TEE, age, diabetes mellitus, and COPD in in-hospital mortality among COVID-19 patients (Table 3) . Previous reports identified both the relationship of COVID-19 infection and TEE [5, 6, [21] [22] [23] and the increased risk of death among TEE patients [24] . However, most of them have been limited in size and focused on patients with severe disease hospitalized in intensive care units. These aspects could explain the significantly lower observed TEE risk in our investigation than in others. We have confirmed the association of D-dimer levels and TEE events [24] . In initial reports of COVID-19 infection, D-dimers levels and prolonged prothrombin time have defined a coagulation disorder associated with COVID-19 infection severity [1] . In line with this hypothesis, recent autopsy studies identified extensive extracellular fibrin deposition and the presence of fibrin thrombi within small vessels and capillaries of the lungs [25] [26] [27] . As in our study, VTE is the most described thrombotic complication [6, 28] . COVID-19 infection was also associated with hyperviscocity, which could explain anticoagulation failures [29] . Moreover, in cases of sepsis the overproduction of proinflammatory cytokines can cause microvasculature and endothelial dysfunction, which could trigger hemostatic cascade [30] . In addition, the prothrombotic effect of COVID-19 infection might be related with the risk of developing acute coronary syndrome, that increases on acute infections like influenza epidemics [31] [32] [33] due to the increment of myocardial demands triggered by infections [34] . Also, there is an evidence of increasing in-hospital mortality among patients with myocardial injury associated with elevated troponin T levels [35, 36] . As well, a direct viral infection of vascular endothelium and myocardium is possible [37, 38] . Stroke mechanisms include hypercoagulability and cardioembolic stroke of cited virus-related with cardiac injury [10] . The absence of association between general risk factors for TEE in our cohort was similar with previous studies [6, 39] . As in other respiratory viral infections [31, 40] , we observed that old patients [7, 41, 42] and COPD [43] were associated with a higher risk of poor outcomes or death. Recent data indicate that diabetes is an important risk factor for unfavorable outcome in COVID-19 patients. However, most of the studies described a small number of cases [7, 19, 42] . Our investigation included enough patients to demonstrated independent predictive value of this risk factor on mortality. This relationship could be partially explained because diabetic patients are predisposed to a hyper-inflammatory and pro-coagulant state [44] . COVID-19 infection could cause pleiotropic alterations of glucose metabolism due to direct effect on angiotensin-converting enzyme 2 (ACE2) receptors of pancreatic beta cells [45] .

Our study has some important limitations as well. First, the retrospective nature of the study might constraint the dataset. Second, we analyzed data supplied by HM Hospitales and it would have been beneficial to perform a revision of the electronic medical records of the included patients, concretely the TEE group to refine some of the variables and get a deeper description. Third, information of previous treatments like anticoagulants or antiplatelet agents was not available. Fourth, we were not able to evaluate a relevant cofounder such as the motivation of hospitalization (clinical or surgical). These limitations avoid us making a recommendation of thrombosis prophylaxis although, due to the large number of patients included we considered that our sample is representative of a larger population. A recent meta-analysis concluded that there is currently insufficient evidence to determine the risks and benefits of prophylactic anticoagulants for people hospitalized with COVID-19 [46] .

In conclusion, the analysis of this multicenter retrospective observational dataset of COVID-19 patients confirmed some of the previous observations related with TEE in COVID-19 patients. The prevalence of TEE was not negligible. In addition, patients who develop TEE such as patients with other comorbidities as diabetes, COPD, and older patients had worse prognosis than patient without TEE or theses comorbidities. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

World Health World Health Organization

Defining the Epidemiology of Covid-19-Studies Needed

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic

Anti-inflammatory approaches to ischaemic stroke prevention

C-reactive protein predicts further ischemic events in transient ischemic attack patients

Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

COVID-19 and Cardiovascular Disease

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

PubMed Central PMCID: PMC7190011 at www.icmje. org/coi_disclosure.pdf and declare: support from the Tongji Hospital for Pilot Scheme Project and the Chinese National Thirteenth Five Years Project in Science and Technology, National Commission of Health, People's Republic of China, for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Thrombosis risk associated with COVID-19 infection. A scoping review

Prevalence of Venous Thromboembolism in Critically Ill Patients with COVID-19

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism?

Postmortem Examination of Patients With COVID-19

COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

COVID-19 coagulopathy: an evolving story

Seasonal Influenza Infections and Cardiovascular Disease Mortality

Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

COVID-19 and the cardiovascular system

Cardiac Involvement in a Patient With Coronavirus Disease

Venous thromboembolism in non-critically ill patients with COVID-19 infection

The influence of virus infections on the course of COPD

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Diabetes is a risk factor for the progression and prognosis of COVID-19

New-Onset Diabetes in Covid-19

Prophylactic anticoagulants for people hospitalised with COVID-19

We thank HM Hospitales for making their data publicly available as part of the COVID Data Save Lives project.